| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 84871 |
cas:1096584-62-1 Mal-Val-Cit-PAB-PNP |
146 |
zyl |
2024-12-19 |
| 84872 |
cas:863971-53-3 Fmoc-Val-Cit-PAB-PNP |
156 |
zyl |
2024-12-19 |
| 84873 |
MC-Sq-Cit-PAB-Dolastatin10 ，cas:1941168-65-5，ADC定制 |
170 |
wyh |
2024-12-19 |
| 84874 |
Mal-PEG2-Val-Cit-PAB-OH ADC抗体偶联药物 |
150 |
zyl |
2024-12-19 |
| 84875 |
N3-PEG4-DYKDDDD-Doxorubicin，ADC定制 |
165 |
wyh |
2024-12-19 |
| 84876 |
MA-vc-PAB-DM1 cas:1464051-44-2 |
122 |
zyl |
2024-12-19 |
| 84877 |
DBCO-PEG4-VC-PAB-DMAE-Duocarmycin SA |
189 |
zyl |
2024-12-19 |
| 84878 |
VC-PAB-DMAE-PNU159682 ADC抗体偶联药物 |
149 |
zyl |
2024-12-19 |
| 84879 |
MC-GGFG-DX8951 cas:1600418-29-8 |
131 |
zyl |
2024-12-19 |
| 84880 |
DOTA-NGR NGR肽偶联1,4,7,10-四氮杂环十二烷-N,N’,N”,N”’-四乙酸(DOTA) |
173 |
h |
2024-12-19 |
| 84881 |
N3-PEG4-vc-PAB-Doxorubicin 叠氮PEG修饰维生素C-阿霉素的介绍 |
279 |
zyl |
2024-12-19 |
| 84882 |
DOTA-Ahx-(d-Lys6-GnRH1)DOTA偶联的d-Lys6-GnRH肽 |
180 |
h |
2024-12-19 |
| 84883 |
DOTA-porphyrin 双功能螯合剂DOTA偶联5-(对-氨基-丙烯-氧苯基)-10,15,20-三-(对-羧基-甲基-烯-氧苯基)卟啉 |
198 |
h |
2024-12-19 |
| 84884 |
VC-SECO DUBA analogue，ADC定制 |
153 |
wyh |
2024-12-19 |
| 84885 |
DOTA-H-Lys(Boc)-OH-SWCNTs 赖氨酸胺手柄功能化的单壁碳纳米管偶联DOTA螯合剂 |
147 |
h |
2024-12-19 |
| 84886 |
[DOTA-A1]-ZHER2:S1 抗HER2 ZHER2:S1亲和体分子缀合DOTA |
246 |
h |
2024-12-19 |
| 84887 |
Vc-MMAD cas:1401963-17-4的结构式 |
144 |
zyl |
2024-12-19 |
| 84888 |
DOTA-E(c(RGDfK))大环DOTA偶联双环肽E[c(RGDfK)] |
167 |
h |
2024-12-19 |
| 84889 |
CL2A-SN38，cas:1279680-68-0，ADC定制 |
273 |
wyh |
2024-12-19 |
| 84890 |
DOTA-gluBBN DOTA缀合铃蟾肽类似物 |
159 |
h |
2024-12-19 |
| 84891 |
DOTA-GSG-KCCYSL DOTA缀合物ErbB-2靶向肽KCCYSL |
233 |
h |
2024-12-19 |
| 84892 |
MC-MMAF ， cas:863971-19-1，ADC定制 |
177 |
wyh |
2024-12-19 |
| 84893 |
TCO-PEG4-Fmoc-Gly-Gly-Gly-ADC连接子 |
199 |
zyl |
2024-12-19 |
| 84894 |
模拟肽4-[2-(3,4,5,6-四氢嘧啶-2-基氨基)乙氧基]苯甲酰基-2-[N-(3-氨基-新戊-1-氨基甲酰基)]-氨乙基磺酰基-氨基-β-丙氨酸(IAC)缀合DOTA |
169 |
h |
2024-12-19 |
| 84895 |
DOTA-chCE7 DOTA标记的糖基化单克隆抗L1-CAM抗体chCE7 |
171 |
h |
2024-12-19 |
| 84896 |
Vc-MMAE， cas:646502-53-6，ADC定制 |
248 |
wyh |
2024-12-19 |
| 84897 |
Azido-PEG4-MMAE |
176 |
zyl |
2024-12-19 |
| 84898 |
cas:2055024-59-2，Fmoc-PEG2-Val-Cit-PAB-OH |
185 |
zyl |
2024-12-19 |
| 84899 |
Azide-PEG6-Val-Cit-PAB-PEG6- Biotin，ADC定制 |
174 |
wyh |
2024-12-19 |
| 84900 |
Ga-DOTA-(Asp)n 大环DOTA共轭(Asp)n肽 |
141 |
h |
2024-12-19 |
| 84901 |
cas:1807530-16-0，2-hydroxyethyl disulfide mono-Tosylate- ADC linker |
198 |
zyl |
2024-12-19 |
| 84902 |
DOTA偶联受体特异性肽 |
175 |
h |
2024-12-19 |
| 84903 |
聚乙二醇化DOTA-AHA基GdIII螯合物 PEGylated DOTA-based gadolinium(III) |
200 |
h |
2024-12-19 |
| 84904 |
PAMAM树状大分子DOTA缀合物 PAMAM–DOTA |
181 |
h |
2024-12-19 |
| 84905 |
ALD-tetra-EG-Osu的介绍 |
217 |
zyl |
2024-12-19 |
| 84906 |
SSTR2靶向肽Tyr(3)-奥曲肽(tate) |
326 |
h |
2024-12-19 |
| 84907 |
DOTA-D-Phe(1)-Tyr(3)-Octreotide |
175 |
h |
2024-12-19 |
| 84908 |
cas:55750-63-5，Mal-heptanoic NHS ester |
207 |
zyl |
2024-12-19 |
| 84909 |
DOTA-Fab-PEG24-EGF DOTA-PEG修饰曲妥珠单抗Fab片段偶联表皮生长因子 |
177 |
h |
2024-12-19 |
| 84910 |
cas:663599-10-8，DMAC-SPP |
190 |
zyl |
2024-12-19 |
| 84911 |
多甲基化的1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)配体 |
219 |
h |
2024-12-19 |
| 84912 |
PEG-pGlu(DOTA)8-LA4 |
105 |
h |
2024-12-19 |
| 84913 |
cas:937025-17-7，2,5-Dioxopyrrolidin-1-yl 2-oxo-6,9,12,15-tetraoxa-3-thiaoctadecan-18-oate |
193 |
zyl |
2024-12-19 |
| 84914 |
DOTA-Hyd-TRP PET示踪剂 |
172 |
h |
2024-12-19 |
| 84915 |
Ga-DOTATOC Ga-DOTA-D-Phe-Tyr-奥曲肽 |
251 |
h |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询